Safinamide for the treatment of Parkinson's disease
| Autor: | Anthony H.V. Schapira, Ruth Mary deSouza |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Levodopa Benzylamines Parkinson's disease Deep brain stimulation medicine.medical_treatment Dopamine Dopamine Agents Context (language use) Pharmacology Antiparkinson Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Physical medicine and rehabilitation medicine Humans Pharmacology (medical) Randomized Controlled Trials as Topic Safinamide Alanine business.industry Dopaminergic Parkinson Disease General Medicine medicine.disease 030104 developmental biology Treatment Outcome chemistry Dyskinesia Quality of Life medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Expert opinion on pharmacotherapy. 18(9) |
| ISSN: | 1744-7666 |
| Popis: | Introduction: The major unmet needs in the medical treatment of Parkinson disease (PD) are reduction of motor side effects from dopaminergic drugs, management of non-motor symptoms and disease modification.Areas covered: Motor fluctuations and OFF periods are a significant determinant of quality of life in PD and reducing their duration and severity can significantly improve motor function. This aim may be partly facilitated by the development of effective adjunctive drugs for dopamine replacement. Safinamide (Xadago), which is a first generation anticonvulsant, has pharmacological properties which are of interest in the context of neurodegenerative diseases, leading to research into its potential as an adjunct to levodopa in PD.Expert opinion: Although its mechanism has not been fully defined, safinamide provides enhanced symptom control of motor function in advanced PD and improves quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|